Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time and motion study of subcutaneous fixed-dose combination of pertuzumab and trastuzumab in HER2-positive early breast cancer
2020-004241-36Phase 4Active
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Average healthcare professional time per patient per visit. Started Feb 2021; status: active.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-004241-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004241-36.